Webinars
White Paper & Webinar:
This report, the seventh in our Trinity Drug Index series, outlines key themes and emerging trends in the industry as we progress towards a new world of targeted and innovative products. We provide a comprehensive evaluation of the performance of novel drugs approved by the FDA in 2021, scoring each on its commercial performance, therapeutic value and R&D investment.
2021 saw 40 unique drug and biologic approvals, of which ~33% (13/40) were Oncology, followed by ~18%…
Read Now
Webinars
Available On Demand
There is no room for missteps along the journey to evaluate the viability of assets in early stages of development. When making go/no go decisions, many critical questions must be answered across the early asset lifecycle.Join a team of cross-functional experts from Trinity Life Sciences for a lively panel discussion on how to approach early commercial assessment with insight from various perspectives. The team will share real-life examples highlighting what life sciences companies need to be thinking about and common…
Watch Now
Briefs
The “molecular optimizer” archetype is a strategy utilized by first-launch companies to optimize existing molecules when developing their first product. Companies using this approach tend to be small and emerging biotech firms that are seeking a foothold to enter the market.
The primary benefit of this approach is that the method offers a higher probability of regulatory approval and streamlines the manufacturer’s path to commercialization. With these benefits come some challenges related to access and pricing of a new product…
Read Now
Webinars
Available On Demand
Did you know 62% of products launched between September 2019 and December 2021 underperformed expectations in the first year of launch?
What is going wrong, and how can we get it right? Join Trinity Life Sciences for a thought-provoking webinar to dive into the first white paper in our Industry Impact Series, Picking Winners: Portfolio Management for a New Era.
Hear from Trinity’s Leslie Orne, President & CEO, Herman Sanchez, Chief Business Officer and Chad Faulkner, Partner, as they explore the challenges…
Watch Now
White Papers
The biopharmaceutical industry is known for its promise of life-changing innovations, but many companies continue to advance the wrong therapies into the clinic, resulting in underperformance and wasted resources. This white paper explores the concentration of activity on well-trodden ground, and the lack of focus on true innovation. With increasing global pricing pressures and policy changes, it is more important than ever to be selective about the drugs that are advanced into the market. This white paper offers insights and…
Read Now
White Papers
This report, the sixth in our Trinity Drug Index series, outlines key themes and emerging trends in the industry as we progress towards a new world of targeted and innovative products. We provide a comprehensive evaluation of the commercial performance over three years of novel drugs approved by the FDA in 2020, with commercial, therapeutic value and R&D investment scores for each. 2020 saw 58 unique drug and biologic approvals, of which the majority were Oncology (29%) followed by Neurology…
Read Now
White Papers
This report, the fifth in our Trinity Drug Index series, outlines key themes and emerging trends in the industry as we progress towards a new world of targeted and innovative products. We provide a comprehensive evaluation of the performance of novel drugs approved by the FDA in 2019, scoring each on its commercial performance, therapeutic value, and R&D investment. 2019 saw 53 unique drug and biologic approvals, of which the majority were neurology (~23%) followed by oncology (~21%). In this…
Read Now
Webinars
Available On Demand
Trinity invites life sciences executives to join us for a dynamic discussion on the most common high-impact challenges inherent in Business Development:
What contributes to inaccurate pricing and market access assumptions in the quick-paced Business Development process?
How do you de-risk pricing and access at each stage of the diligence process?
Chad Faulkner, Partner in Trinity’s Strategic Advisory practice, will host this session and moderate a panel with special guests Monica Martin De Bustamante—Senior Partner & Head of Evidence, Value,…
Watch Now
Webinars
Available On Demand
Secure success in bringing your novel therapies to market with Trinity’s innovative, holistic approach to valuing early-stage assets.
Biopharma companies have been experiencing record levels of growth in recent years through M&A, co-developments, joint ventures, licensing agreements and other partnership deals. It is unlikely that this accelerated growth would have been sustained using traditional methodologies that are less able to generate realistic valuations for complex innovative therapies. Using traditional valuation methods, we likely would not have seen the commercialization of…
Watch Now
White Papers
With more momentum than ever to bring innovative medicines to market, there is increased pressure on emerging companies to get the launch right. The industry has seen record-breaking funding for therapies in recent years, and many have been commercialized by emerging biopharma companies launching for the first time. For many of these emerging biopharma companies, optimizing commercial launch spend is a critical consideration pre- and post-launch, and with limited funds it can be easy to misjudge the timing of key…
Read Now
